Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neus Llarch

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
European Journal of Cancer (Oxford, England : 1990)|May 3, 2026
Corrigendum to "Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes" [Eur J Cancer (May) (2025) 15:221:115404]Marta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Journal of Hepatology|October 28, 2025
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 updateMaria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, et al.
Journal of Hepatology|April 5, 2026
Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654]Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, et al.
Journal of Hepatology|December 2, 2021
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodulesMarco Sanduzzi-Zamparelli, Zoe Mariño, Sabela Lens, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Alimentary Pharmacology & Therapeutics|February 23, 2026
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)Marco Sanduzzi-Zamparelli, Ana Matilla, José Luis Lledo, et al.
Journal of Hepatology|February 7, 2026
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinomaJean-Charles Nault, Claudia Campani, Theo Z Hirsch, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2025
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular CarcinomaJean-Charles Nault, Claudia Campani, Theo Z Hirsch, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
European Journal of Cancer (Oxford, England : 1990)|May 3, 2026
Corrigendum to "Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes" [Eur J Cancer (May) (2025) 15:221:115404]Marta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Journal of Hepatology|October 28, 2025
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 updateMaria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, et al.
Journal of Hepatology|April 5, 2026
Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654]Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, et al.
Journal of Hepatology|December 2, 2021
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodulesMarco Sanduzzi-Zamparelli, Zoe Mariño, Sabela Lens, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Alimentary Pharmacology & Therapeutics|February 23, 2026
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)Marco Sanduzzi-Zamparelli, Ana Matilla, José Luis Lledo, et al.
Journal of Hepatology|February 7, 2026
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinomaJean-Charles Nault, Claudia Campani, Theo Z Hirsch, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2025
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular CarcinomaJean-Charles Nault, Claudia Campani, Theo Z Hirsch, et al.
Pageof 3